Study terminated early due to business decision.

ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A administered orally (PO) once daily (QD) in 28-day cycles in patients with relapsed/resistant or refractory advanced hematologic malignancies [Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), indolent NHL, and other NHL subtypes).](streamdown:incomplete-link)

The ZX-101A-101 study will consist of 2 parts:

• Part 1: ZX-101A Dose Escalation
• Part 2: ZX-101A Dose Expansion

The Part 1 (dose escalation) of the study is designed to determine the safety and tolerability of ZX-101A administered orally once daily in 28-day cycles. The Part 2 (dose expansion) of the study is designed to further investigate the safety, tolerability, pharmacokinetics and pharmacodynamic and clinical activities of ZX-101A administered orally once daily in 28-day cycles at the selected recommended Phase 2 dose (RP2D).

Results of clinical findings in patients in the dose-escalation portion of the study will be reviewed to identify conditions (or genetic characteristics) most likely to respond to ZX-101A. These select types of hematologic malignancies will be enrolled in cohorts in the dose-expansion part of the study.

Male or female patients who are 18 years of age or older with relapsed/resistant or refractory advanced hematologic malignancies (CLL/SLL, iNHL, and other NHL subtypes) will be included in the study provided that all inclusion and exclusion criteria are satisfied.

Up to three cohorts are planned in Part 2 - Dose Expansion of the study: 1) relapsed/resistant or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), 2) relapsed/resistant or refractory indolent Non- Hodgkin's Lymphoma (iNHL), and based on emerging data from Part 1-Dose Expansion, a third cohort consisting of other types of NHL may be included.

Inclusion Criteria:

• Males and females who are ≥ 18 years old
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
• Failed at least 2 prior systemic standard therapies.
• Histopathological confirmed diagnosis of CLL/SLL, indolent NHL,and other NHL subtypes.
• Documented active disease that is relapsed/resistant or refractory requiring treatment after established therapy shown to have clinical benefit.
• Acceptable bone marrow, kidney, and liver function.
• No transfusion or cytokine support for ≥ 2 weeks before initiating study treatment.
• Ability to swallow and retain oral medications (see exclusion criteria #20 below).
• Negative serum pregnancy test in women of childbearing potential at Screening.
• Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use effective contraceptive methods.
• Men must agree to no sperm donations during the study and for 3 months after the last dose of ZX-101A.
• Understands the requirements of the study (e.g. periodic imaging studies, periodic blood sampling, bone marrow studies), is willing to comply with all study procedures and signed the Institutional Review Board (IRB)-approved informed consent.

Exclusion Criteria:

• Received investigational study drug within 28 days (or 5 half-lives, whichever is longer).
• Concurrent participation in another therapeutic treatment trial.
• Received approved anti-cancer drugs within 21 days (42 days for nitrosoureas) or 5 half-lives, whichever is longer.
• Ongoing immunosuppression for chronic conditions.
• Known active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV infection.
• Any concurrent uncontrolled illness.
• Has not recovered from adverse events from prior anti-cancer treatment (with exception of alopecia).
• Pregnant or breast-feeding or planning to conceive or father children within the projected duration of the study.
• Major surgery within 4 weeks prior to first dose of study treatment.
• Radiation treatment within 2 weeks prior to first dose of study treatment.
• Gastrointestinal dysfunction, including motility or malabsorption syndromes or inflammatory bowel disease which could limit absorption of study drug.
• Active or prior pneumonitis or interstitial lung disease.

Other inclusion and exclusion criteria may apply.